ZAThis article explains the differences between three weight-loss medications—Ozempic, Wegovy, and Mounjaro—that are gaining attention in South Africa. It clarifies that while all three are injectable and linked to weight loss, they have distinct active ingredients, approved uses, and risk profiles. Ozempic contains semaglutide and is approved for type 2 diabetes, not weight loss, making its use for that purpose off-label. Wegovy is also semaglutide but is specifically approved for chronic weight management. Mounjaro contains tirzepatide, which affects both GLP-1 and GIP receptors and is approved for type 2 diabetes. The article highlights the importance of regulatory distinctions in South Africa, noting that public confusion and the availability of counterfeit products affect access to these treatments.
Tendenz-Einschätzung (Mitte): The article presents factual information about the medical distinctions between three drugs without taking a political stance. It focuses on health regulations, drug approvals, and patient considerations, which are non-political in nature. The tone remains neutral, providing balanced explanations of
